- Home
- CURR vs TLSI Comparison
CURR vs TLSI Comparison
Compare CURR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- TLSI
- Stock Information
- Founded
- CURR 2013
- TLSI 2010
- Country
- CURR Singapore
- TLSI United States
- Employees
- CURR N/A
- TLSI N/A
- Industry
- CURR Business Services
- TLSI Medical Specialities
- Sector
- CURR Consumer Discretionary
- TLSI Health Care
- Exchange
- CURR Nasdaq
- TLSI Nasdaq
- Market Cap
- CURR 151.4M
- TLSI 150.0M
- IPO Year
- CURR N/A
- TLSI N/A
- Fundamental
- Price
- CURR $1.60
- TLSI $4.71
- Analyst Decision
- CURR Strong Buy
- TLSI Strong Buy
- Analyst Count
- CURR 1
- TLSI 5
- Target Price
- CURR $3.50
- TLSI $10.90
- AVG Volume (30 Days)
- CURR 162.0K
- TLSI 102.3K
- Earning Date
- CURR 08-04-2025
- TLSI 11-13-2025
- Dividend Yield
- CURR N/A
- TLSI N/A
- EPS Growth
- CURR N/A
- TLSI N/A
- EPS
- CURR N/A
- TLSI N/A
- Revenue
- CURR $41,092,419.00
- TLSI $35,990,000.00
- Revenue This Year
- CURR N/A
- TLSI $56.79
- Revenue Next Year
- CURR $14.56
- TLSI $54.15
- P/E Ratio
- CURR N/A
- TLSI N/A
- Revenue Growth
- CURR N/A
- TLSI 45.50
- 52 Week Low
- CURR $0.33
- TLSI $3.42
- 52 Week High
- CURR $7.08
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- CURR 50.53
- TLSI 51.35
- Support Level
- CURR N/A
- TLSI N/A
- Resistance Level
- CURR $1.71
- TLSI $5.10
- Average True Range (ATR)
- CURR 0.12
- TLSI 0.26
- MACD
- CURR -0.08
- TLSI -0.23
- Stochastic Oscillator
- CURR 88.61
- TLSI 88.51
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.